The Signatera assay showed positive correlations between ctDNA presence and cancer recurrence, suggesting its potential for ...
We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...
There are multiple potential applications for circulating tumor (ct)DNA in kidney cancer. The post-nephrectomy remission, adjuvant therapy decision, and monitoring for response or progression on ...
ctDNA test, which is an important aspect in liquid biopsy, offers a non-invasive alternative to tissue biopsies for cancer diagnosis and monitoring. Ultra-deep ctDNA sequencing enabling the detection ...
The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive ...
Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...
Please provide your email address to receive an email when new articles are posted on . Patients with limited-stage small cell lung cancer with ctDNA positivity after chemotherapy had significant ...
In this study, researchers aimed to determine whether ctDNA is detectable in other bodily fluids besides blood, and to characterize any ctDNA they were able to detect.
A groundbreaking study reveals that ultrasensitive ctDNA assays significantly enhance prognosis for large B-cell lymphoma, outperforming traditional PET assessments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback